Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ST3
MCID: SPP010
MIFTS: 51

Suppressor of Tumorigenicity 3 (ST3)

Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Suppressor of Tumorigenicity 3

About this section

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 57 71
Cervical Carcinoma 57 13 54 17
Cervical Carcinoma, Tumor-Suppressor Gene Involved in; Ccts 57
Cervical Carcinoma, Tumor-Suppressor Gene Involved in 57
Tumor-Suppressor Gene, Hela Cell Type; Tshl 57
Tumor-Suppressor Gene, Hela Cell Type 57
Cervix Carcinoma 71
Tshl 57
Ccts 57
St3 57

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 191181
UMLS 71 C0302592 C1860658
Sources

Summaries for Suppressor of Tumorigenicity 3

About this section
MalaCards based summary : Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to squamous cell papilloma and in situ carcinoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cellular Senescence (REACTOME). The drugs Metronidazole and Vortioxetine have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and breast, and related phenotypes are hematopoietic system and homeostasis/metabolism

More information from OMIM: 191181
Sources

Related Diseases for Suppressor of Tumorigenicity 3

About this section

Diseases in the Suppressor of Tumorigenicity 3 family:

Suppressor of Tumorigenicity 11

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.4 TP53 CDKN2A
2 in situ carcinoma 31.4 TP53 MYC CDKN2A
3 cervix uteri carcinoma in situ 31.2 TP53 RB1 FHIT CDKN2A
4 cervical squamous cell carcinoma 31.1 TP53 MYC CDKN2A
5 chronic cervicitis 30.9 TP53 CDKN2A
6 cervix carcinoma 30.8 TP53 MYC FHIT CDKN2A
7 cervical adenocarcinoma 30.5 TP53 MYC CDKN2A CDKN1A
8 papilloma 30.5 UBE3A TP53 RB1 CDKN2A CDKN1A
9 keratinizing squamous cell carcinoma 30.3 TP53 CDKN2A
10 retinoblastoma 30.2 TP53 RB1 MYC CDKN2A CDKN1A
11 squamous cell carcinoma 30.1 TP53 RB1 MYC FHIT CDKN2A CDKN1A
12 human papillomavirus infectious disease 30.1 TP53 FHIT CDKN2A CDKN1A
13 endocervical adenocarcinoma 30.0 TP53 CDKN2A CDKN1A
14 adenocarcinoma 30.0 TP53 RB1 MYC CDKN2A CDKN1A BCL2
15 adenocarcinoma in situ 29.9 CDKN2A CDKN1A CA9
16 retinitis pigmentosa 11 29.9 TP53 MYC CDKN2A
17 penile cancer 29.8 TP53 RB1 CDKN2A
18 anal squamous cell carcinoma 29.8 TP53 CDKN2A
19 anogenital venereal wart 29.7 UBE3A TP53 RB1 CDKN2A
20 vulva cancer 29.7 TP53 CDKN2A CA9
21 adult t-cell leukemia 29.7 TP53 MYC CDKN2A
22 b-lymphoblastic leukemia/lymphoma 29.6 RB1 MYC CDKN2A
23 gallbladder cancer 29.6 TP53 FHIT CDKN2A
24 vaginal cancer 29.6 UBE3A TP53 CDKN2A
25 anus cancer 29.6 UBE3A TP53 CDKN2A
26 endometrial cancer 29.6 TP53 RB1 MYC CDKN2A CDKN1A BCL2
27 b-cell lymphoma 29.5 TP53 MYC CDKN2A CDKN1A BCL2
28 oral cancer 29.5 TP53 FHIT CDKN2A CDKN1A
29 glioblastoma 29.4 TP53 RB1 MYC CDKN2A CDKN1A
30 malignant astrocytoma 29.4 TP53 MYC CDKN2A CA9
31 osteogenic sarcoma 29.4 TP53 RB1 MYC CDKN2A CDKN1A
32 skin melanoma 29.3 TP53 MYC CDKN2A CDKN1A
33 cervical cancer 29.3 UBE3A TP53 RB1 MYC FHIT CDKN2A
34 basal cell carcinoma 29.1 TP53 CDKN2A CDKN1A BCL2
35 kidney cancer 29.1 TP53 FHIT CDKN2A CA9
36 myelodysplastic syndrome 29.1 TP53 MYC FHIT CDKN2A CDKN1A
37 rhabdomyosarcoma 29.1 TP53 RB1 MYC CDKN2A CDKN1A
38 nasopharyngeal carcinoma 29.0 TP53 MYC CDKN2A CA9 BCL2
39 lymphoma 29.0 TP53 RB1 MYC CDKN2A BCL2
40 fibrosarcoma 29.0 TP53 MYC CDKN1A CA9
41 burkitt lymphoma 28.8 TP53 RB1 MYC CDKN2A CDKN1A BCL2
42 melanoma 28.8 TP53 RB1 MYC CDKN2A CDKN1A BCL2
43 lung cancer susceptibility 3 28.8 TP53 RB1 MYC FHIT CDKN2A CDKN1A
44 esophageal cancer 28.4 TP53 RB1 MYC FHIT CDKN2A CDKN1A
45 bladder cancer 27.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
46 pancreatic cancer 27.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
47 squamous cell carcinoma, head and neck 27.7 TP53 RB1 MYC FHIT CDKN2A CDKN1A
48 high-grade neuroendocrine carcinoma of the cervix uteri 11.0
49 cervical adenosquamous carcinoma 11.0
50 cervical intraepithelial neoplasia 10.8

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:



Diseases related to Suppressor of Tumorigenicity 3
Sources

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

About this section

Clinical features from OMIM®:

191181 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
2 homeostasis/metabolism MP:0005376 10.13 BCL2 CDKN1A CDKN2A FHIT MYC PLIN3
3 digestive/alimentary MP:0005381 10.1 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
4 endocrine/exocrine gland MP:0005379 10.08 BCL2 CA9 CDKN1A CDKN2A MYC RB1
5 immune system MP:0005387 10.06 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
6 integument MP:0010771 10.02 BCL2 CDKN1A CDKN2A FHIT MYC RB1
7 mortality/aging MP:0010768 10.02 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
8 adipose tissue MP:0005375 9.99 BCL2 CDKN1A MYC PLIN3 RB1 TP53
9 neoplasm MP:0002006 9.76 BCL2 CDKN1A CDKN2A FHIT MYC RB1
10 muscle MP:0005369 9.73 BCL2 CDKN1A CDKN2A MYC RB1 TP53
11 no phenotypic analysis MP:0003012 9.43 CDKN1A CDKN2A MYC RB1 TP53 UBE3A
12 pigmentation MP:0001186 9.02 BCL2 CDKN2A MYC RB1 TP53
Sources

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

About this section

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
2
Vortioxetine Approved, Investigational Phase 3 508233-74-7 9966051
3
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
4
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
5
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Gemcitabine Approved Phase 3 95058-81-4 60750
8
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
9
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
10
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
11
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
12
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
13
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
14
Tirapazamine Investigational Phase 3 27314-97-2
15 Endostar protein Phase 3
16 Endostatins Phase 3 71581480
17 Antidepressive Agents Phase 3
18 Serotonin Receptor Agonists Phase 3
19 Serotonin Uptake Inhibitors Phase 3
20 Neurotransmitter Agents Phase 3
21 Antiprotozoal Agents Phase 2, Phase 3
22 Antiparasitic Agents Phase 2, Phase 3
23 Psychotropic Drugs Phase 3
24 Serotonin 5-HT1 Receptor Agonists Phase 3
25 Anti-Anxiety Agents Phase 3
26 Serotonin 5-HT3 Receptor Antagonists Phase 3
27 Anesthetics Phase 3
28 Tin Fluorides Phase 3
29 Antimitotic Agents Phase 3
30 Tubulin Modulators Phase 3
31 Folic Acid Antagonists Phase 3
32 topoisomerase I inhibitors Phase 3
33 Albumin-Bound Paclitaxel Phase 3
34 Antineoplastic Agents, Immunological Phase 3
35 Immunoglobulins Phase 3
36 Antibodies Phase 3
37 Antibodies, Monoclonal Phase 3
38 Vaccines Phase 3
39 Vinca Alkaloids Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
42
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2, 11096-26-7
43
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
44
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
45
Mycophenolic acid Approved Phase 2 24280-93-1 446541
46
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
47
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
48
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
49
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
50
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Cardiac Coherence Training to Reduce Anxiety in Remitted Schizophrenia Completed NCT02390271 Phase 4
2 Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer Unknown status NCT02595554 Phase 3 Paclitaxel;Cisplatin
3 A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma Unknown status NCT03086681 Phase 3 Endostar;DDP
4 A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy. Unknown status NCT01414517 Phase 3
5 Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma Unknown status NCT01000415 Phase 3
6 Controlled Cord Traction During Third Stage of Labor: Pilot Trial Completed NCT00781066 Phase 3
7 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
8 Collaborative Corneal Transplantation Studies (CCTS) Completed NCT00000137 Phase 3
9 An Open-label, Long-Term Extension Study to Assess the Safety and Efficacy of Lu AA21004 in Patients With Major Depressive Disorder (Extension to Lu AA21004/CCT-003 Study) Completed NCT01395147 Phase 3 Lu AA21004
10 Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma" Completed NCT02083211 Phase 3 mAb Nimotuzumab
11 EARLYdrain - Prospective Outcome Study of Early Lumbar Drainage in Aneurysmal Subarachnoid Hemorrhage Completed NCT01258257 Phase 3
12 A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005) Recruiting NCT02629718 Phase 3 NACT (Paclitaxel + Cisplatin or carboplatin)
13 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
14 Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunológica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer") Active, not recruiting NCT03728881 Phase 3
15 Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma Active, not recruiting NCT01554397 Phase 2, Phase 3 Cisplatin
16 An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma Active, not recruiting NCT03257267 Phase 3 Cemiplimab;Investigator Choice (IC) Chemotherapy
17 Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line. Active, not recruiting NCT03413579 Phase 3
18 Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma Active, not recruiting NCT00806117 Phase 3
19 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
20 An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma Unknown status NCT00292955 Phase 2 Cetuximab
21 Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma. Unknown status NCT00039884 Phase 2 NESP - Novel Erythropoiesis Stimulating Protein
22 HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma: Clinical Trial Completed NCT02523365 Phase 1, Phase 2
23 A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) Completed NCT00081263 Phase 2 Celecoxib
24 Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma. Completed NCT03540407 Phase 2
25 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
26 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin
27 A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
28 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
29 A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma Completed NCT00257816 Phase 2 Topotecan;Cisplatin
30 Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study Completed NCT00184093 Phase 1, Phase 2 Gemcitabine
31 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
32 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
33 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
34 Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma Completed NCT00003445 Phase 2 docetaxel
35 Efficacy of Using Bifidobacterium Lactis CCT 7858 in Improving Gastrointestinal Symptoms in Adults Using Antibiotics Recruiting NCT04742322 Phase 2
36 Combination of Nimotuzumab and Radiotherapy for Recurrent and Metastatic Uterine Cervical Squamous Carcinoma: a Single-arm, Open, Phase 2 Clinical Trial Recruiting NCT04664244 Phase 2
37 Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Single Center, Open, Phase II Trial Recruiting NCT04188860 Phase 2 A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
38 Apatinib Combined With Cisplatin and Paclitaxel as First-line Chemotherapy for Recurrent or Persistent Advanced Cervical Cancer: A Single Arm, Single Center, Open, Phase II Trial Recruiting NCT04188847 Phase 2 Chemotherapy plus apatinib
39 A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma Recruiting NCT03108495 Phase 2
40 Study of Tumor Infiltrating Lymphocytes Following Concurrent Chemoradiotherapy in the Treatment of Patients With Cervical Carcinoma Recruiting NCT04443296 Phase 2 CCRT+TIL;CCRT
41 A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting NCT02584478 Phase 1, Phase 2 AL3818;Carboplatin;Paclitaxel
42 A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure Recruiting NCT04205799 Phase 2 Cabozantinib
43 A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer Active, not recruiting NCT03786081 Phase 1, Phase 2 Tisotumab Vedotin;Bevacizumab;Pembrolizumab;Carboplatin
44 A Dose Escalation and Dose Expansion Trial to Assess the Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) CCT 301-38 or CCT 301-59 in Patients With Recurrent or Refractory Stage IV Renal Cell Carcinoma Active, not recruiting NCT03393936 Phase 1, Phase 2
45 SHR-1210, a Novel Anti-pd-1 Antibody, in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: a Single-arm, Open Label, Multi-center, Phase II Study Active, not recruiting NCT03816553 Phase 2 SHR-1210;Apatinib
46 BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma." Active, not recruiting NCT02009579 Phase 2 Nintedanib;Placebo
47 A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies Active, not recruiting NCT01693783 Phase 2
48 A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy. Not yet recruiting NCT04652076 Phase 1, Phase 2 NP137;Pembrolizumab;Paclitaxel;Carboplatin
49 FIGO 2018 Stage IB2 (≥2cm - <4 cm) Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F) Not yet recruiting NCT04483557 Phase 2 Paclitaxel, SUB09583MIG
50 A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer Terminated NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Sources

Genetic Tests for Suppressor of Tumorigenicity 3

About this section
Sources

Anatomical Context for Suppressor of Tumorigenicity 3

About this section

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

40
Cervix, Lymph Node, Breast, Uterus, Endothelial, Skin, Bone
Sources

Publications for Suppressor of Tumorigenicity 3

About this section

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 10684)
# Title Authors PMID Year
1
Interstitial deletion of 11q13 sequences in HeLa cells. 61 57
10959095 2000
2
Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. 61 57
7887426 1995
3
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 61 57
8041728 1994
4
Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. 57 61
1680288 1991
5
Genetic characteristics of the HeLa cell. 61 57
1246620 1976
6
Cell culture forensics. 57
11438719 2001
7
Short tandem repeat profiling provides an international reference standard for human cell lines. 57
11416159 2001
8
East Hela and West Hela, in memory of Stella Mamaeva, 1939-1995. 57
8964054 1996
9
Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome II. 57
2577469 1989
10
Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. 57
2881780 1986
11
Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. 57
2877730 1986
12
Suppression of tumorigenicity in somatic cell hybrids. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intraspecies hybrids of normal diploid x malignant cells. 57
3956263 1986
13
Suppression of tumorigenicity. 57
7140370 1982
14
Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. 57
7323948 1981
15
Cross-contamination of cells in culture. 57
6451928 1981
16
Characteristics of HeLa strains: permanent vs. variable features. 57
7002488 1980
17
Suppression of tumorigenicity in somatic cell hybrids. I. Suppression and reexpression of tumorigenicity in diploid human X D98AH2 hybrids and independent segregation of tumorigenicity from other cell phenotypes. 57
6934067 1980
18
Suppression of malignancy in human cells. 57
1264187 1976
19
HeLa cultures defined. 57
1246601 1976
20
Banded marker chromosomes as indicators of intraspecies cellular contamination. 57
4469665 1974
21
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. 57
4942173 1971
22
Apparent Hela cell contamination of human heteroploid cell lines. 57
5641128 1968
23
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. 61 54
20351093 2010
24
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. 54 61
20067769 2010
25
Constitutive HIF-1 activity in malignant melanoma. 54 61
20185296 2010
26
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 61 54
20429915 2010
27
HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. 54 61
20026098 2010
28
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 61 54
20395210 2010
29
Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. 54 61
19953094 2010
30
Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. 61 54
19362787 2009
31
Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. 54 61
19935879 2009
32
[Involvement of human papillomavirus in upper aero-digestive tracts cancers]. 61 54
19744917 2009
33
HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. 61 54
19775342 2009
34
Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. 61 54
19427027 2009
35
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. 61 54
19589137 2009
36
Antitumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA in malignant melanoma cells. 61 54
19441892 2009
37
The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. 54 61
19563645 2009
38
Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells. 61 54
19216720 2009
39
The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. 54 61
18716870 2009
40
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. 61 54
19202550 2009
41
[Inhibitive effect of E1A gene on the cell growth of human cervical carcinoma cell in vitro]. 61 54
19483289 2009
42
Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. 54 61
19476635 2009
43
Immunohistochemical studies of trophoblastic tumors. 61 54
19145204 2009
44
Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. 54 61
19327639 2009
45
Differential tissue-specific protein markers of vaginal carcinoma. 54 61
19367286 2009
46
No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population. 61 54
19263211 2009
47
Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. 54 61
19251084 2009
48
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. 54 61
19148475 2009
49
Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma. 61 54
19331227 2009
50
Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. 54 61
19100258 2009
Sources

Variations for Suppressor of Tumorigenicity 3

About this section
Sources

Expression for Suppressor of Tumorigenicity 3

About this section
Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.
Sources

Pathways for Suppressor of Tumorigenicity 3

About this section

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
GPCR Pathway 63
Show member pathways
 13.62 UBE3A TP53 RB1 MYC CDKN2A CDKN1A
2
Cellular Senescence (REACTOME) 65
Show member pathways
 13.06 TP53 RB1 CDKN2A CDKN1A CA9
3
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.99 TP53 RB1 MYC CDKN1A BCL2
4
PI3K-Akt signaling pathway 36
Show member pathways
 12.95 UBE3A TP53 RB1 MYC CDKN1A BCL2
5
Human cytomegalovirus infection 36
Show member pathways
 12.87 TP53 TAP1 RB1 MYC CDKN2A CDKN1A
6
Endometrial cancer 36
Show member pathways
 12.84 TP53 RB1 MYC CDKN2A CDKN1A BCL2
7
Pathways in cancer 36
12.81 TP53 RB1 MYC CDKN2A CDKN1A BCL2
8
Measles 36
Show member pathways
 12.79 TP53 TAP1 RB1 MYC CDKN1A BCL2
9
Gastric cancer 36
Show member pathways
 12.72 TP53 RB1 MYC CDKN2A CDKN1A BCL2
10
Chks in Checkpoint Regulation 63
Show member pathways
 12.67 TP53 RB1 MYC CDKN1A BCL2
11
Apoptosis Modulation and Signaling 1
Show member pathways
 12.67 TP53 MYC CDKN2A CDKN1A BCL2
12
Glioma 36
Show member pathways
 12.63 TP53 RB1 FHIT CDKN2A CDKN1A BCL2
13
ErbB signaling pathway 36 1
Show member pathways
 12.56 TP53 MYC CDKN1A BCL2
14
Mitotic G1-G1/S phases 65
Show member pathways
 12.55 TP53 RB1 MYC CDKN2A CDKN1A
15
Immune response IL-23 signaling pathway 23
Show member pathways
 12.53 TP53 MYC CDKN1A BCL2
16
MicroRNAs in cancer 36
12.52 TP53 MYC CDKN2A CDKN1A BCL2
17
DNA Damage 4
12.47 TP53 RB1 CDKN2A CDKN1A
18
Cell cycle 36 1
12.35 TP53 RB1 MYC CDKN2A CDKN1A
19
Cyclins and Cell Cycle Regulation 63
Show member pathways
 12.33 TP53 RB1 CDKN2A CDKN1A
20
Human T-cell leukemia virus 1 infection 36
12.32 TP53 RB1 MYC CDKN2A CDKN1A
21
DNA Damage Response 1
Show member pathways
 12.28 TP53 RB1 MYC CDKN2A CDKN1A BCL2
22
Viral carcinogenesis 36
12.27 UBE3A TP53 RB1 CDKN2A CDKN1A
23
p53 Signaling 63
Show member pathways
 12.24 TP53 RB1 CDKN1A BCL2
24
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.22 TP53 RB1 MYC CDKN1A BCL2
25
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.21 RB1 MYC CDKN2A CDKN1A
26
Integrated Breast Cancer Pathway 1
12.14 TP53 RB1 MYC BCL2
27
Cellular senescence (KEGG) 36
12.13 TP53 RB1 MYC CDKN2A CDKN1A
28
Colorectal Cancer Metastasis 63
12.11 TP53 MYC CDKN1A
29
Direct p53 effectors 1
12.03 TP53 TAP1 RB1 CDKN1A BCL2
30
TGF-beta Signaling Pathway (WikiPathways) 1
12.01 TP53 MYC CDKN1A
31
Interleukin-4 and 13 signaling 65
11.98 TP53 MYC CDKN1A BCL2
32
Spinal Cord Injury 1
11.96 TP53 RB1 MYC
33
DNA Damage Response (only ATM dependent) 1
11.95 TP53 MYC CDKN2A CDKN1A BCL2
34
Glioblastoma Multiforme 63
11.92 TP53 RB1 MYC CDKN2A CDKN1A
35
Senescence and Autophagy in Cancer 1
11.88 TP53 RB1 CDKN2A CDKN1A BCL2
36
Retinoblastoma (RB) in Cancer 1
11.85 TP53 RB1 MYC CDKN1A
37
Androgen receptor signaling pathway 1
11.83 UBE3A RB1 CDKN1A
38
C-MYB transcription factor network 1
11.76 MYC CDKN1A BCL2
39
Platinum drug resistance 36
11.73 TP53 CDKN2A CDKN1A BCL2
40
E2F transcription factor network 1
11.72 RB1 MYC CDKN1A
41
Validated targets of C-MYC transcriptional repression 1
11.64 MYC CDKN1A BCL2
42
Bladder cancer 36 1
11.63 TP53 RB1 MYC CDKN2A CDKN1A
43
Hepatitis C and Hepatocellular Carcinoma 1
11.56 TP53 MYC CDKN1A
44
miRNAs involved in DNA damage response 1
11.55 TP53 MYC CDKN1A
45
Aryl Hydrocarbon Receptor 1
11.53 RB1 MYC CDKN1A
46
Transcription_P53 signaling pathway 23
11.53 UBE3A TP53 RB1 CDKN2A CDKN1A BCL2
47
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.47 TP53 MYC CDKN1A
48
Small cell lung cancer 36
11.4 TP53 RB1 MYC FHIT CDKN1A BCL2
49
Photodynamic therapy-induced AP-1 survival signaling. 1
11.36 TP53 RB1 CDKN2A CDKN1A BCL2
50
Integrated Cancer Pathway 1
11.22 TP53 RB1 MYC CDKN1A BCL2
Sources

GO Terms for Suppressor of Tumorigenicity 3

About this section

Cellular components related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.02 TP53 MYC CDKN2A CDKN1A BCL2

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.97 TP53 RB1 FHIT CDKN2A BCL2
2 negative regulation of cell proliferation GO:0008285 9.91 TP53 RB1 CDKN2A CDKN1A BCL2
3 cytokine-mediated signaling pathway GO:0019221 9.86 TP53 MYC CDKN1A BCL2
4 response to drug GO:0042493 9.8 TP53 MYC CDKN1A CA9 BCL2
5 rhythmic process GO:0048511 9.79 UBE3A TP53 ENOX2
6 regulation of cell cycle GO:0051726 9.78 TP53 RB1 CDKN1A BCL2
7 cellular response to hypoxia GO:0071456 9.77 TP53 MYC BCL2
8 neuron apoptotic process GO:0051402 9.67 TP53 RB1 BCL2
9 G1/S transition of mitotic cell cycle GO:0000082 9.67 RB1 MYC CDKN2A CDKN1A
10 cellular senescence GO:0090398 9.63 CDKN2A CDKN1A
11 negative regulation of reactive oxygen species metabolic process GO:2000378 9.63 TP53 BCL2
12 negative regulation of mitotic cell cycle GO:0045930 9.63 TP53 RB1 BCL2
13 release of cytochrome c from mitochondria GO:0001836 9.62 TP53 BCL2
14 response to X-ray GO:0010165 9.61 TP53 CDKN1A
15 negative regulation of phosphorylation GO:0042326 9.61 CDKN2A CDKN1A
16 response to gamma radiation GO:0010332 9.61 TP53 MYC BCL2
17 mitotic cell cycle arrest GO:0071850 9.59 TP53 CDKN1A
18 apoptotic mitochondrial changes GO:0008637 9.58 CDKN2A BCL2
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.58 TP53 CDKN1A
20 Ras protein signal transduction GO:0007265 9.56 TP53 RB1 CDKN2A CDKN1A
21 T cell lineage commitment GO:0002360 9.55 TP53 BCL2
22 signal transduction by p53 class mediator GO:0072331 9.54 TP53 CDKN1A
23 B cell lineage commitment GO:0002326 9.52 TP53 BCL2
24 replicative senescence GO:0090399 9.5 TP53 CDKN2A CDKN1A
25 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.46 RB1 CDKN2A CDKN1A BCL2
26 cell cycle arrest GO:0007050 9.35 TP53 RB1 MYC CDKN2A CDKN1A
27 negative regulation of cell growth GO:0030308 9.02 TP53 RB1 CDKN2A CDKN1A BCL2

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 core promoter sequence-specific DNA binding GO:0001046 9.37 TP53 MYC
2 transcription factor binding GO:0008134 9.35 TP53 RB1 MYC CDKN2A BCL2
3 disordered domain specific binding GO:0097718 9.33 TP53 RB1 CDKN2A
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN2A CDKN1A
5 MDM2/MDM4 family protein binding GO:0097371 9.26 TP53 CDKN2A
6 ubiquitin protein ligase binding GO:0031625 9.02 TP53 RB1 FHIT CDKN1A BCL2
Sources

Sources for Suppressor of Tumorigenicity 3

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....